ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Report |**FINAL**

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	3/18/1957
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Primary Biliary Cholangitis Panel
ARUP test code 3002480

Mitochondrial (M2) Antibody, IgG	3.8 Units	(Ref Interval: 0.0-24.9)

REFERENCE INTERVAL: Mitochondrial (M2) Antibody, IgG

```
  20.0 Units or less ......... Negative
  20.1 - 24.9 Units........... Equivocal
  25.0 Units or greater....... Positive
```

Anti-mitochondrial antibodies (AMA) are thought to be present in
90-95% of patients with primary biliary cholangitis (PBC).
However, the frequency of detected antibodies may be cohort or
assay dependent, as lower sensitivities have been reported. Not
all PBC patients are positive for AMA; some patients may be
positive for SP100 and/or GP210 antibodies. A negative result
does not rule out PBC.

Antinuclear Antibody (ANA), HEp-2, IgG	<1:80	(Ref Interval: <1:80)

ANA Interpretive Comment	See Note

Antinuclear antibodies by IFA negative for homogeneous,
speckled, nucleolar, centromere, and nuclear dots patterns.

Cytoplasmic antibodies by IFA negative for reticular/AMA,
discrete/GW body-like, polar/golgi-like, rods and rings, and
cytoplasmic speckled patterns.

INTERPRETIVE INFORMATION: ANA Interpretive Comment

Presence of antinuclear antibodies (ANA) is a hallmark feature
of systemic autoimmune rheumatic diseases (SARD). However, ANA
lacks diagnostic specificity and is associated with a variety of
diseases (cancers, autoimmune, infectious, and inflammatory
conditions) and may also occur in healthy individuals in
varying prevalence. The lack of diagnostic specificity requires
confirmation of positive ANA by more specific serologic tests.
ANA (nuclear reactivity) positive patterns reported include
centromere, homogeneous, nuclear dots, nucleolar, or speckled.
ANA (cytoplasmic reactivity) positive patterns reported include
reticular/AMA, discrete/GW body-like, polar/golgi-like,
cytoplasmic speckled or rods and rings. All positive patterns
are reported to endpoint titers (1:2560). Reported patterns may
help guide differential diagnosis, although they may not be
specific for individual antibodies or diseases. Mitotic staining
patterns not reported. Negative results do not necessarily rule
out SARD.

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-250-105328
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 1 of 2 | Printed: 9/26/2023 11:09:35 AM
4848

ARUP LABORATORIES

800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Report |**FINAL**

Anti-gp210 Antibody, IgG | 2.2 Units | (Ref Interval: 0.0-24.9)

REFERENCE INTERVAL: Anti-gp210 Antibody, IgG

```
20.0 Units or less........Negative
20.1-24.9 Units..........Equivocal
25.0 Units or greater.....Positive
```

GP210 IgG antibodies can be detected in patients with primary biliary cholangitis (PBC) and may be of diagnostic relevance in a subset of patients with PBC who are negative for anti-mitochondrial antibodies (AMA). These antibodies have a relatively low sensitivity with excellent specificity for PBC. A negative result does not rule out PBC.

Anti-sp100 Antibody, IgG | 1.5 Units | (Ref Interval: 0.0-24.9)

REFERENCE INTERVAL: Anti-sp100 Antibody, IgG

```
20.0 Units or less........Negative
20.1-24.9 Units..........Equivocal
25.0 Units or greater.....Positive
```

SP100 IgG antibodies can be detected in patients with primary biliary cholangitis (PBC) and may be of diagnostic relevance in a subset of patients with PBC who are negative for anti-mitochondrial antibodies (AMA). These antibodies have a relatively low sensitivity with excellent specificity for PBC. A negative result does not rule out PBC.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Mitochondrial (M2) Antibody, IgG	23-250-105328	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Antinuclear Antibody (ANA), HEp-2, IgG	23-250-105328	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
ANA Interpretive Comment	23-250-105328	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Anti-gp210 Antibody, IgG	23-250-105328	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Anti-sp100 Antibody, IgG	23-250-105328	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-250-105328
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 2 | Printed: 9/26/2023 11:09:35 AM
4848